Georgia is ranked fifth highest among states for rates of HIV diagnosis. About 4% of persons living with HIV infection in the United States reside in Georgia, and almost 19% of these people do not know their HIV status. The present study examined the trends and associated factors of HIV testing among adults in Georgia between 2010 and 2014 by analyzing data of the Behavioral Risk Factor Surveillance System (BRFSS). A total of 30,791 persons aged ≥18 years were identified who responded to the question “Have you ever been tested for HIV?” Overall, there were 11,543 respondents who had been tested for HIV, with a decrease in percentage from 49.4% in 2010 to 43.7% in 2014 (p<0.001). Factors associated with HIV testing were being black (p<0.001), being younger than 55 years (p<0.001), single (p=0.02), attaining education level above high school (P<0.001), engaging in HIV high-risk behaviors (p<0.001), and not having healthcare coverage (p=0.03). Overall in Georgia, there has been a decline in the temporal trend of HIV testing, and more than half of adults have never been tested for HIV. For reducing HIV transmission in Georgia, enhancing access and utilization of HIV testing should be a public health priority.

We evaluated progress towards animal biodiversity research in Georgia, a key area in the Caucasus biodiversity hotspot. By reviewing recently (1990-2018) published articles in all areas of animal diversity research, we unmasked the trends in biodiversity inventory, ecological and biogeographical studies, and conservation issues in Georgia. We concluded that species inventory and biodiversity research in Georgia has significantly increased during the last ten years, however the rate and extent of investigation is far from satisfactory. Major gaps remain in all branches of animal diversity research in Georgia, and consequently existing knowledge is inadequate to address modern challenges related to species and ecosystem conservation. We urge local governmental authorities and international scientific societies to support development of stronger research facilities and cultivate interest in biodiversity inventory and research in Georgia as an important step towards maintaining globally important biodiversity in the Caucasus.

Despite a global push in the development and implementation of widespread alternative energy use, significant disparities exist across given nation-states. These disparities reflect both technical and economic factors, as well as the social, political, and ecological gaps between how communities see energy development and national/global policy goals. Known as the “local-national gap,” many nations struggle with fostering meaningful conversations about the role of alternative energy technologies within communities. Mitigation of this problem first requires understanding the distribution of existing alternative energy technologies at the local level of policymaking. Using the State of Georgia, U.S.A. as a case study, we present a model for analyzing how existing adoption trends enable/limit conversation at the scale of local governance (i.e., county governments). Leveraging existing work on the Gini Coefficient as a metric for measuring energy inequity, we argue these tools can be applied to analyze where gaps exist in ongoing solar adoption trends. As we demonstrate, communities that adopt solar tend to be concentrated in a few counties, indicating existing conversations are limited to a circumscribed set of social networks. This information and the model we demonstrate can enable focused qualitative analyses of existing solar trends, not only amongst high-adoption areas but within communities where little to no adoption has occurred.

Background Healthcare workers (HCWs) have suffered considerable morbidity and mortality during the COVID-19 pandemic. Few data on COVID-19 vaccine effectiveness (VE) are available from middle-income countries in Europe. We evaluated primary series COVID-19 VE against laboratory-confirmed COVID-19 among HCWs in Georgia. Methods HCWs in six hospitals in Georgia were invited to enroll in a prospective cohort study conducted during March 19–December 5, 2021. Participants completed weekly symptom questionnaires. Symptomatic HCWs were tested by RT-PCR and/or rapid antigen test (RAT), and participants were routinely tested for SARS-CoV-2 by RT-PCR or RAT, regardless of symptoms. Serology was collected at enrolment, and quarterly thereafter, and tested by electrochemiluminescence immunoassay for SARS-CoV-2 antibodies. We defined primary series vaccination as two doses of COVID-19 vaccine received ≥14 days before symptom onset. We estimated VE as (1-hazard ratio)*100 using a Cox proportional hazards model with vaccination status as a time-varying covariate. Estimates were adjusted by potential confounders that changed the VE estimate by more than 5%, according to the change-in-estimate approach. Results Overall, 1561/3849 (41%) eligible HCWs enrolled and were included in the analysis. The median age was 40 (IQR: 30-53), 1318 (84%) were female, and 1003 (64%) had laboratory evidence of prior SARS-Cov-2 infection. At enrolment, 1300 (83%) were unvaccinated; By study end, 1082 (62%) had completed a primary vaccine series (69% BNT162b2 (Pfizer-BioNTech); 22% BBIBP-CorV (Sinopharm); 9% other). During the study period, 191(12%) participants had a new PCR- or RAT-confirmed symptomatic SARS-CoV-2 infection. VEa gainst PCR- or RAT- confirmed symptomatic SARS-CoV-2 infection was 58 (95%CI: 41; 70) for all primary series vaccinations, 68% (95%CI: 51; 79) for BNT162b2, and 40% (95%CI: 1; 64) for BBIBP-CorV vaccines. Among previously infected HCWs, VE was 58% (95%CI: 11; 80). VE against medically attended COVID-19 was 52% (95%CI: 28; 68), and VE against hospitalization was 69% (95% CI: 36; 85). During the period of predominant Delta variant circulation (July-December 2021), VE against symptomatic COVID-19 was 52% (95%CI: 30; 66). Conclusions Primary series vaccination with BNT162b2 and BBIBP-CorV was effective at preventing COVID-19 among HCWs, most of whom had previous infection, during a period of mainly Delta circulation. Our results support the utility of COVID-19 primary vaccine series, and the importance of increasing coverage, even among previously infected individuals.